Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

41.69USD
15 Feb 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$41.69
Open
$43.15
Day's High
$43.28
Day's Low
$40.05
Volume
876,591
Avg. Vol
780,539
52-wk High
$111.36
52-wk Low
$29.26

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -1.40 -- --
ROI: -53.15 8.92 14.45
ROE: -- 10.08 15.96

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

15 Feb 2019

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

15 Feb 2019

Earnings vs. Estimates